tiprankstipranks
Trending News
More News >
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
US Market
Advertisement

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Compare
1,784 Followers
See the Price Targets and Ratings of:

JAZZ Analyst Ratings

Strong Buy
15Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JAZZ Stock 12 Month Forecast

Average Price Target

$184.69
▲(44.57% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $184.69 with a high forecast of $230.00 and a low forecast of $147.00. The average price target represents a 44.57% change from the last price of $127.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"107":"$107","138":"$138","169":"$169","200":"$200","231":"$231"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$230.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":184.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$184.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$147.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[107,138,169,200,231],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,115.52,124.32615384615384,133.13230769230768,141.93846153846152,150.74461538461537,159.55076923076922,168.35692307692307,177.16307692307691,185.96923076923076,194.7753846153846,203.58153846153846,212.3876923076923,221.19384615384615,{"y":230,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,115.52,120.84076923076923,126.16153846153846,131.4823076923077,136.80307692307693,142.12384615384616,147.4446153846154,152.76538461538462,158.08615384615385,163.40692307692308,168.7276923076923,174.04846153846154,179.36923076923077,{"y":184.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,115.52,117.94153846153846,120.36307692307692,122.78461538461538,125.20615384615384,127.6276923076923,130.04923076923077,132.47076923076924,134.8923076923077,137.31384615384616,139.73538461538462,142.15692307692308,144.57846153846154,{"y":147,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":114.38,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.04,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.58,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$230.00Average Price Target$184.69Lowest Price Target$147.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on JAZZ
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$162$185
Buy
44.81%
Upside
Reiterated
08/29/25
Goldman Sachs Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on JAZZ
Truist Financial
Truist Financial
$200$205
Buy
60.47%
Upside
Reiterated
08/28/25
Analysts Offer Insights on Healthcare Companies: Prothena (NASDAQ: PRTA) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Needham Analyst forecast on JAZZ
Needham
Needham
$202
Buy
58.12%
Upside
Initiated
08/28/25
Optimistic Buy Rating for Jazz Pharmaceuticals Driven by Strategic Launch of Modeyso and Advancements in Global Phase 3 Study
Stifel Nicolaus Analyst forecast on JAZZ
Stifel Nicolaus
Stifel Nicolaus
$230
Buy
80.04%
Upside
Reiterated
08/28/25
Stifel Nicolaus Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Analyst forecast on JAZZ
Morgan Stanley
Morgan Stanley
$162$163
Buy
27.59%
Upside
Reiterated
08/28/25
Morgan Stanley Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Piper Sandler Analyst forecast on JAZZ
Piper Sandler
Piper Sandler
$147
Buy
15.07%
Upside
Reiterated
08/28/25
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Piper Sandler
TD Cowen Analyst forecast on JAZZ
TD Cowen
TD Cowen
$205
Buy
60.47%
Upside
Reiterated
08/28/25
TD Cowen Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Leerink Partners Analyst forecast on JAZZ
Leerink Partners
Leerink Partners
Buy
Reiterated
08/27/25
Analysts' Top Healthcare Picks: Privia Health Group (PRVA), Jazz Pharmaceuticals (JAZZ)
RBC Capital Analyst forecast on JAZZ
RBC Capital
RBC Capital
$145$151
Buy
18.20%
Upside
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Healthequity (NASDAQ: HQY), Serina Therapeutics (NYSE MKT: SER) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Bank of America Securities Analyst forecast on JAZZ
Bank of America Securities
Bank of America Securities
$225
Buy
76.13%
Upside
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (NASDAQ: ACRV) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Robert W. Baird Analyst forecast on JAZZ
Robert W. Baird
Robert W. Baird
$155$160
Buy
25.24%
Upside
Reiterated
08/07/25
Robert W. Baird Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
Deutsche Bank  Analyst forecast on JAZZ
Deutsche Bank
Deutsche Bank
$152$154
Buy
20.55%
Upside
Reiterated
08/07/25
Deutsche Bank Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
J.P. Morgan Analyst forecast on JAZZ
J.P. Morgan
J.P. Morgan
$209$204
Buy
59.69%
Upside
Reiterated
08/06/25
Jazz Pharmaceuticals (JAZZ) Receives a Buy from J.P. Morgan
Wells Fargo Analyst forecast on JAZZ
Wells Fargo
Wells Fargo
$170
Buy
33.07%
Upside
Reiterated
07/18/25
Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)
Raymond James Analyst forecast on JAZZ
Raymond James
Raymond James
Hold
Reiterated
06/11/25
Raymond James Keeps Their Hold Rating on Jazz Pharmaceuticals (JAZZ)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on JAZZ
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$162$185
Buy
44.81%
Upside
Reiterated
08/29/25
Goldman Sachs Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on JAZZ
Truist Financial
Truist Financial
$200$205
Buy
60.47%
Upside
Reiterated
08/28/25
Analysts Offer Insights on Healthcare Companies: Prothena (NASDAQ: PRTA) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Needham Analyst forecast on JAZZ
Needham
Needham
$202
Buy
58.12%
Upside
Initiated
08/28/25
Optimistic Buy Rating for Jazz Pharmaceuticals Driven by Strategic Launch of Modeyso and Advancements in Global Phase 3 Study
Stifel Nicolaus Analyst forecast on JAZZ
Stifel Nicolaus
Stifel Nicolaus
$230
Buy
80.04%
Upside
Reiterated
08/28/25
Stifel Nicolaus Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Analyst forecast on JAZZ
Morgan Stanley
Morgan Stanley
$162$163
Buy
27.59%
Upside
Reiterated
08/28/25
Morgan Stanley Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Piper Sandler Analyst forecast on JAZZ
Piper Sandler
Piper Sandler
$147
Buy
15.07%
Upside
Reiterated
08/28/25
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Piper Sandler
TD Cowen Analyst forecast on JAZZ
TD Cowen
TD Cowen
$205
Buy
60.47%
Upside
Reiterated
08/28/25
TD Cowen Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Leerink Partners Analyst forecast on JAZZ
Leerink Partners
Leerink Partners
Buy
Reiterated
08/27/25
Analysts' Top Healthcare Picks: Privia Health Group (PRVA), Jazz Pharmaceuticals (JAZZ)
RBC Capital Analyst forecast on JAZZ
RBC Capital
RBC Capital
$145$151
Buy
18.20%
Upside
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Healthequity (NASDAQ: HQY), Serina Therapeutics (NYSE MKT: SER) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Bank of America Securities Analyst forecast on JAZZ
Bank of America Securities
Bank of America Securities
$225
Buy
76.13%
Upside
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (NASDAQ: ACRV) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Robert W. Baird Analyst forecast on JAZZ
Robert W. Baird
Robert W. Baird
$155$160
Buy
25.24%
Upside
Reiterated
08/07/25
Robert W. Baird Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
Deutsche Bank  Analyst forecast on JAZZ
Deutsche Bank
Deutsche Bank
$152$154
Buy
20.55%
Upside
Reiterated
08/07/25
Deutsche Bank Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
J.P. Morgan Analyst forecast on JAZZ
J.P. Morgan
J.P. Morgan
$209$204
Buy
59.69%
Upside
Reiterated
08/06/25
Jazz Pharmaceuticals (JAZZ) Receives a Buy from J.P. Morgan
Wells Fargo Analyst forecast on JAZZ
Wells Fargo
Wells Fargo
$170
Buy
33.07%
Upside
Reiterated
07/18/25
Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)
Raymond James Analyst forecast on JAZZ
Raymond James
Raymond James
Hold
Reiterated
06/11/25
Raymond James Keeps Their Hold Rating on Jazz Pharmaceuticals (JAZZ)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

1 Month
xxx
Success Rate
26/42 ratings generated profit
62%
Average Return
+0.66%
initiated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +0.66% per trade.
3 Months
xxx
Success Rate
24/38 ratings generated profit
63%
Average Return
+0.83%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.16% of your transactions generating a profit, with an average return of +0.83% per trade.
1 Year
Annabel SamimyStifel Nicolaus
Success Rate
20/30 ratings generated profit
67%
Average Return
+5.11%
reiterated a buy rating 7 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.11% per trade.
2 Years
xxx
Success Rate
18/30 ratings generated profit
60%
Average Return
+5.28%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +5.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
11
18
21
18
24
Buy
29
19
18
23
25
Hold
2
1
2
1
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
38
41
42
54
In the current month, JAZZ has received 49 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 184.69.
Each month's total comprises the sum of three months' worth of ratings.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is $5.96 with a range of $5.38 to $6.47. The previous quarter’s EPS was -$8.25. JAZZ beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.
Next quarter’s earnings estimate for JAZZ is $5.96 with a range of $5.38 to $6.47. The previous quarter’s EPS was -$8.25. JAZZ beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $1.11B with a range of $1.07B to $1.13B. The previous quarter’s sales results were $1.05B. JAZZ beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.28% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.
Next quarter’s sales forecast for JAZZ is $1.11B with a range of $1.07B to $1.13B. The previous quarter’s sales results were $1.05B. JAZZ beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.28% of the time in the same period. In the last calendar year JAZZ has Outperformed its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 184.69.
    What is JAZZ’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 44.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JAZZ a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s price target?
            The average price target for Jazz Pharmaceuticals is 184.69. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $230.00 ,the lowest forecast is $147.00. The average price target represents 44.57% Increase from the current price of $127.75.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of JAZZ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis